// App-Quantinova.ai

851 : Rituximab Maintenance Significantly Prolongs Event Free (EFS) and Progression Free Survival (PFS) In Male Patients With Aggressive B-Cell Lymphoma In The NHL13 Study

Researchers

Presenter

  • Ulrich Jaeger

Principal Investigators

  • Helen Melzer

  • Liang-Tsai Hsiao

  • Wing-Yan Au

  • Josef Thaler

  • Gerhard Weidinger

  • Felix Keil

  • Christian Dittrich

  • Cathrin Skrabs

  • Daniela Wolkersdorfer

  • Anton Klingler

  • Richard Greil

  • Michael Praxmarer

  • David Goldstein

  • Michael A. Fridrik

  • Weerasak Nawarawong

  • Dina Ben Yehuda

  • Biljana Mihaljevic

  • Osman Ilhan

  • Veronika Ballova

  • Michael Hedenus

Medical Centers

  • Department of Internal Medicine, Sundsvall Hospital, Sundsvall, Sweden

  • Dept. of Medicine I, Division of Hematology and Hemostaseology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria

  • Blood Med Clinic, Hong Kong, China

  • IIIrd Medical Department, Salzburg Cancer Research Institute, Paracelsus Medical University, Salzburg, Austria

  • 3rd Dpt. of Medicine, AKH-Linz, Linz, Austria

  • NOU, Klenova Bratislava, Slovakia

  • LBI-ACR & ACR-ITR VIEnna, KFJ-Spital, Vienna, Austria

  • Medical University of Vienna, Vienna, Austria

  • Division of Hematology-Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

  • Clinic of Nephrology, Clinical Center of Serbia, Belgrade, Serbia

  • Department of Radiology, Hacettepe University School of Medicine, Ankara, Turkey

  • Medical University of Vienna, Dept. of Medicine I, Division of Hematology and Hemostaseology, Comprehensive Cancer Center, Vienna, Austria

  • st Medical Department, Landesklinikum Wiener Neustadt, Wiener Neustadt, Austria

  • Division of Hematology, Faculty of Medicine, Chiang Mai University, Muang, Chiang Mai, Thailand

  • Arbeitsgemeinschaft Medikamentose Tumortherapie, AGMT, Salzburg, Austria

  • Dept. of Medicine, Hadassah - Hebrew University Medical Center, Jerusalem, Israel

  • Department of Internal Medicine IV, Klinikum Wels-Grieskirchen, Wels, Austria

  • Med. Dept. for Hematology and Oncology, Hanusch Krankenhaus, Vienna, Austria

  • Department of Dermatology, Charles University, Prague, Czech Republic

  • Australasian Leukaemia & Lymphoma Group, East Melbourne, Australia

Locations

  • Czech Republic

  • China

  • Taiwan

  • Austria

  • Turkey

  • Australia

  • Thailand

  • Israel

  • Serbia

  • Slovakia

  • Sweden

Companies

  • Assign Data Manageme

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Follicular lymphoma

  • B cell lymphomas

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Rituximab

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved